|1.||Quinn, Joseph F: 3 articles (12/2011 - 01/2011)|
|2.||Anekonda, Thimmappa S: 3 articles (12/2011 - 01/2011)|
|3.||Wadsworth, Teri L: 2 articles (09/2011 - 01/2011)|
|4.||Woltjer, Randall L: 2 articles (09/2011 - 01/2011)|
|5.||Surmeier, D James: 2 articles (12/2010 - 03/2009)|
|6.||Flynn, Joseph T: 2 articles (11/2010 - 09/2002)|
|7.||Wang, P: 2 articles (12/2005 - 06/2004)|
|8.||Alekhin, S N: 2 articles (09/2002 - 01/2002)|
|9.||Svetyĭ, L I: 2 articles (09/2002 - 01/2002)|
|10.||Johnson, B A: 2 articles (08/2001 - 05/2000)|
|1.||Hypertension (High Blood Pressure)
02/01/1991 - "In conclusion, these results indicate that isradipine is a novel drug which is highly effective and well tolerated in the treatment of mild to moderate hypertension in this group of patients."
12/01/1991 - "Thus, isradipine proved effective and very well tolerated and may deserve a place as first line treatment for hypertension."
09/01/1991 - "This study indicates that intravenous isradipine is an effective therapy with sustained efficacy for intraoperative hypertension during abdominal surgery. "
02/15/1990 - "Isradipine was more effective in patients whose clinical hypertension was confirmed by ambulatory BP monitoring (35) than in patients who remained normotensive by ambulatory BP monitoring criteria (41). "
03/01/2002 - "Isradipine is effective in the treatment of arterial hypertension following CABG. "
01/01/1992 - "On this basis, a 3-year clinical trial is being carried out in the United States--the Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS)--to establish the efficacy of isradipine in inhibiting atherogenesis and retarding the progression of atherosclerosis in carotid arteries of hypertensive patients. "
04/01/1995 - "Since the earlier review in Drugs substantial additional data have accumulated regarding the antihypertensive efficacy of isradipine in various clinical situations, as well as data on its clinical effects in atherosclerosis. "
01/01/1991 - "Therefore, we hypothesized that isradipine may be appropriate for testing the efficacy of antihypertensive treatment in retarding the progression of atherosclerosis in humans. "
01/01/1990 - "Thus, isradipine may be a suitable drug for assessing the efficacy of antihypertensive treatment in retarding the progression of atherosclerosis. "
01/01/2000 - "The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) showed a higher incidence of angina and more frequent cardiovascular events in patients treated with isradipine. "
01/30/1987 - "These interim results suggest that PN 200-110 will prove to be an effective and safe drug for the treatment of angina pectoris."
04/17/1989 - "Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris."
04/01/1994 - "In this placebo-controlled, double-blind, parallel-group design study we evaluated the duration of effects and safety of isradipine 10 mg bid in male patients with chronic stable angina pectoris. "
01/01/1994 - "The primary purpose of this study was to determine whether treatment with isradipine would prevent an exercise-induced increase in the concentration of anuclear carcasses of endothelial cells in the blood of men with angina pectoris. "
04/17/1989 - "Five hundred ninety outpatients aged 18 years or older with stable angina pectoris entered a multicenter, single-blind, nonrandomized, baseline-controlled study to assess the efficacy, safety, and tolerability of isradipine in doses of 2.5, 5, or 7.5 mg three times daily for 12 weeks, following a two-week placebo "washout" period. "
04/17/1989 - "The hemodynamic response achieved by isradipine is balanced; there is a marked decrease in total peripheral resistance with no clinically significant tachycardia or cardiodepressant effect, no fluid retention (natriuretic/diuretic effect) or orthostatic reactions, whereas the blood flow to vital organs is preserved. "
12/01/1986 - "Isradipine appears to be effective in lowering blood pressure without reflex tachycardia."
01/01/1993 - "Due to its negative chronotropic properties, the reflex tachycardia was significantly attenuated after isradipine as compared to the other drugs (heart-rate changes: NIF +13 +/- 7%, p < 0.01; ISR +4 +/- 7%, not significant; NIS +20 +/- 10%, p < 0.01; FEL +17 +/- 12%, p < 0.01). "
11/01/1990 - "Long-term experience with isradipine indicates that the antihypertensive efficacy is maintained without problems of tachycardia or tachyphylaxis."
02/01/1990 - "Sustained monomorphic tachycardias were inducible in five pigs before and in three pigs after isradipine, and no deterioration of the signal-averaged electrocardiogram parameters was found.(ABSTRACT TRUNCATED AT 250 WORDS)"
11/01/1995 - "Given before and after ischemia in the mouse, isradipine was also ineffective, whereas SB201823A produced a significant reduction in lesion volume. "
01/01/1992 - "We conclude that isradipine has a beneficial effect on the clinical and electrocardiographic signs of exercise-induced ischemia, leading to a significant improvement of the systolic and diastolic parameters of left ventricular function. "
06/01/1999 - "Use of diffusion-weighted MRI and neurological deficit scores to demonstrate beneficial effects of isradipine in a rat model of focal ischemia."
05/01/1997 - "After normothermic global ischemia, the Bmax of [3H]isradipine binding increased in the left ventricle by 81% (299% +/- 1.7% to 540% +/- 11% fmoles/mg, P < 0.01) and in the right ventricle by 33% (387% +/- 9.9% to 515% +/- 38% fmoles/mg, P < 0.01) compared with control. "
11/01/1995 - "In this fraction, the yield for PN 200-110 binding sites was 4.7 +/- 0.6% in the control condition and 2.8 +/- 0.5% after ischemia (P < 0.05). "
|1.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|3.||Transplantation (Transplant Recipients)